Screener
CRISPR Therapeutics CRSP Acquired In Process Research And Development Previously Included In Research And Development
Acquired In Process Research And Development Previously Included In Research And Development at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept crsp:AcquiredInProcessResearchAndDevelopmentPreviouslyIncludedInResearchAndDevelopment.
The source filing: CRISPR Therapeutics’s 10-K, filed February 12, 2026. Open the filing →
- Filed
- Feb 12, 2026, 4:59 PM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-048957
FAQ
- What is CRISPR Therapeutics's acquired in process research and development previously included in research and development?
- CRISPR Therapeutics (CRSP) reported acquired in process research and development previously included in research and development of $625K in Q4 2023.
- What does acquired in process research and development previously included in research and development mean?
- Captures the reclassification of research and development expenses that were previously categorized as acquired in-process R&D. This metric helps investors track the transition of acquired assets from initial acquisition accounting into active, ongoing research programs. It provides transparency into the lifecycle of external innovation within the company's R&D portfolio.
Ask your AI about CRISPR Therapeutics's acquired in process research and development previously included in research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude